Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China

被引：0

作者：

Lu, S. ^{[1
]}

Shen, L. ^{[1
]}

Wang, Q. ^{[2
,8
]}

Chen, H. ^{[2
]}

Zhao, Y. ^{[3
]}

Li, Y. ^{[3
]}

Segall, G. ^{[4
]}

Dyachkova, Y. ^{[5
]}

Khanal, M. ^{[6
]}

Zhang, X. ^{[7
]}

Ding, D. ^{[7
]}

Shao, J.

Wang, Q. ^{[2
,8
]}

Gao, Y. ^{[8
]}

Pang, L. ^{[8
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China

[2] Henan Canc Hosp, Dept Oncol, Zhengzhou, Peoples R China

[3] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China

[4] Eli Lilly & Co, Bracknell, Berks, England

[5] Eli Lilly GmbH, Vienna, Austria

[6] Eli Lilly & Co, Indianapolis, IN 46285 USA

[7] Eli Lilly & Co, Shanghai, Peoples R China

[8] IQVIA, Real World Solut, Shanghai, Peoples R China

来源：

关键词：

RET NSCLC; biomarker; treatment; patterns;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP07.04-15

引用

页码：S550 / S551

页数：2